

## Guidance for Use of Previously Approved Lines from NIH hESC Registry in CIRM-Funded Research

On March 29, 2010 the Independent Citizens Oversight Committee (ICOC) of the California Institute for Regenerative Medicine reaffirmed its intent that <u>stem cell lines previously approved by NIH</u> be treated as "acceptably derived" materials for the purpose of conducting CIRM-funded research. As a result of this action, researchers may continue to utilize lines previously approved by NIH without additional review by a stem cell research oversight committee.

The ICOC reiterated that additional lines may also be used in CIRM-funded research provided that they satisfy CIRM's "acceptably derived" standard, including approval by an IRB or an IRB-like entity for international lines where necessary.